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Quantification of risk factors for postherpetic
neuralgia in herpes zoster patients
A cohort study
ABSTRACT
Objective: To investigate risk factors for postherpetic neuralgia, the neuropathic pain that com-
monly follows herpes zoster.
Methods: Using primary care data from the Clinical Practice Research Datalink, we fitted multi-
variable logistic regression models to investigate potential risk factors for postherpetic neuralgia
(defined as pain $90 days after zoster, based on diagnostic or prescription codes), including
demographic characteristics, comorbidities, and characteristics of the acute zoster episode.
We also assessed whether the effects were modified by antiviral use.
Results: Of 119,413 zoster patients, 6,956 (5.8%) developed postherpetic neuralgia. Postherpetic
neuralgia risk rose steeply with age, most sharply between 50 and 79 years (adjusted odds ratio [OR]
for a 10-year increase, 1.70, 99% confidence interval 1.63–1.78). Postherpetic neuralgia risk was
higher in women (6.3% vs 5.1% in men: OR 1.19, 1.10–1.27) and those with severely immunosup-
pressive conditions, including leukemia (13.7%: 2.07, 1.08–3.96) and lymphoma (12.7%: 2.45,
1.53–3.92); autoimmune conditions, including rheumatoid arthritis (9.1%: 1.20, 0.99–1.46); and
other comorbidities, including asthma and diabetes. Current and ex-smokers, as well as underweight
and obese individuals, were at increased risk of postherpetic neuralgia. Antiviral use was not asso-
ciated with postherpetic neuralgia (OR 1.04, 0.97–1.11). However, the increased risk associated
with severe immunosuppression appeared less pronounced in patients given antivirals.
Conclusions: Postherpetic neuralgia risk was increased for a number of patient characteristics
and comorbidities, notably with age and among those with severe immunosuppression. As zoster
vaccination is contraindicated for patients with severe immunosuppression, strategies to prevent
zoster in these patients, which could include the new subunit zoster vaccine, are an increasing
priority. Neurology® 2016;87:94–102
GLOSSARY
adjOR 5 adjusted odds ratio; BMI 5 body mass index; CI 5 confidence interval; CKD 5 chronic kidney disease; COPD 5
chronic obstructive pulmonary disease; CPRD 5 Clinical Practice Research Datalink; GP 5 general practitioner; HES 5
Hospital Episode Statistics; IBD 5 inflammatory bowel disease; ICD-10 5 International Classification of Diseases–10;
OR 5 odds ratio; PHN 5 postherpetic neuralgia; RA 5 rheumatoid arthritis; SLE 5 systemic lupus erythematosus.
Postherpetic neuralgia (PHN) is the commonest complication of herpes zoster1 and may cause
severe pain.2 The lifetime incidence of zoster is 30% and an estimated 12.5% of zoster patients
aged $50 years develop PHN.3 Symptoms can persist for months or years, often profoundly
affecting a patient’s quality of life.4 There are no known effective disease-modifying therapies for
PHN. Treatments target symptom control, yet are often inadequate at relieving pain and are
ineffective in almost half of patients with PHN.5–7
To date, observational and trial data have provided inconsistent evidence that administering anti-
virals at rash onset reduces PHN risk.8 These trials also tend to exclude immunosuppressed patients,
such that the efficacy of antivirals to prevent PHN in this patient group is greatly under-researched.
The only proven and available intervention to reduce PHN risk is through varicella-zoster virus
vaccination.9 However, the high cost of the vaccine means many countries limit its coverage.
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A recent review demonstrates our incomplete
understanding of PHN risk factors10,11; except
for age, evidence is conflicting and studies are
often underpowered to detect associations. Con-
sidering the dearth of effective treatment options
for PHN, identifying PHN risk factors to inform
zoster vaccination policy could have important
public health benefits.12
This article aims to quantify risk factors for
PHN in a large prospective study among zoster
patients. It also investigates whether antivirals
modify the effect of these risk factors on PHN.
METHODS Study design and setting. We conducted a study
among zoster patients using prospectively collected data from the
Clinical Practice Research Datalink (CPRD), a large routinely col-
lected UK database of anonymized primary care records. CPRD is
broadly representative of UK patient and practice characteristics.13
Sixty percent of CPRD patients had data available in the Hospital
Episode Statistics (HES) database (version 9), a linked database of
hospital attendances in England from 1997. Clinical diagnoses are
coded in CPRDwith Read codes and in HES with ICD-10 codes.13
Study population. The study cohort included patients with
first ever zoster (identified previously14), followed up to determine
who develops PHN. Briefly, these patients were diagnosed with
zoster between January 1, 2000, and December 31, 2011, in
CPRD (Read code for zoster and .12 months follow-up in
CPRD before zoster diagnosis [to ensure the code represented
incident zoster]) or HES (ICD-10 code for zoster in the
primary diagnosis field of any episode). The zoster vaccine was
introduced into the United Kingdom in 2013, therefore this was
an unvaccinated population.
Definition of PHN. Our underlying definition of PHN was
pain persisting$90 days following zoster diagnosis.7 The primary
definition of PHN included patients classified as having diag-
nosed, probable, or possible PHN, based on a validated algorithm
of PHN within a US administrative database utilizing diagnosis
codes and prescription data.15 See table 1 for full definition.
Exclusions. As anticonvulsant prescriptions were part of our
PHN algorithm (table 1), patients with other indications for
anticonvulsants (e.g., epilepsy) recorded pre-zoster were excluded.
We also excluded patients without 365 days follow-up after zoster
diagnosis; we could not know whether individuals censored
before 365 days without PHN met our PHN definition, which
used data to 365 days.
Risk factors of interest. Demographic risk factors included age
at zoster, sex, and socioeconomic status. Comorbidities included
severely immunosuppressive conditions, specifically a recent history
(,2 years before zoster diagnosis) of leukemia or lymphoma, or any
history of HIV, hematopoietic stem cell transplantation, myeloma,
or other unspecified cellular immune deficiencies (e.g., pancytope-
nia),$14-day course of high-dose ($20 mg/d) oral corticosteroids,
or exposure to other immunosuppressive therapies, in the month
prior to zoster diagnosis. Other comorbidities included autoimmune
conditions (systemic lupus erythematosus [SLE], rheumatoid
arthritis [RA], inflammatory bowel disease [IBD]), diabetes,
chronic obstructive pulmonary disease (COPD), asthma, chronic
kidney disease (CKD), personality disorder, recent depression, and
recent cancer. Other characteristics included smoking, body mass
index (BMI), site of acute zoster rash, and antivirals given within 7
days of zoster diagnosis (see appendix e-I on the Neurology® Web
site at Neurology.org for further details on risk factor definitions).
Statistical analysis. Crude and age-adjusted odds ratios (ORs)
were calculated to estimate the strength of association of each
potential risk factor with PHN at 90 days (defined above), using
logistic regression. The age–PHN association was nonlinear;
therefore age was modeled as a 5-knot restricted cubic spline. To
numerically summarize the effect of nonlinear age on PHN risk, we
also fitted piecewise linear models (see appendix e-II for further
details on modeling of age).
Multivariable analyses using logistic regression were carried
out on patients with complete data for all variables. All variables
were included in the final model. Two models were built, first
excluding then including immunosuppressive therapies, to assess
whether some of the overall effects of diseases were mediated by
their treatments.
Antivirals given at zoster may modify the risk of PHN. Antivi-
rals are given to approximately 60% of patients with zoster in
CPRD.16 We calculated stratum-specific ORs for each variable in
the multivariable model by whether patients received antivirals.
Patients potentially receiving antivirals in hospital were excluded
from this analysis. In a post hoc analysis, we also calculated the
adjusted OR for the effect of antivirals on PHN risk among patients
with immunosuppression using logistic regression.
Finally, a potentially effect-modifying role of age was investi-
gated by computing stratum-specific ORs for each variable in the
multivariable model by age groups ,70 years and $70 years as
well as ,60 years and $60 years (age groups chosen to reflect
Table 1 Postherpetic neuralgia (PHN) classifications
Diagnosed PHN
PHN codea (90–365 days post-zoster)
Probable PHN
Zoster code and prescription consistent with PHNb on same day (90–365 days post-zoster)
Nonspecific neuralgia code (90–365 days post-zoster)
New anticonvulsant or capsaicin cream or lidocaine patch prescription (90–180 days
post-zoster)
New tricyclic antidepressants 90–180 days post-zoster with no other indication on the day of
the prescription, plus evidence of the drug being prescribed for zoster or PHN previouslyc
Possible PHN
New tricyclic antidepressants 90–180 days post-zoster with no other indication on the day of
the prescription
New strong painkiller 90–180 days following zoster with no other indication on the day of the
prescription, plus evidence of the drug being prescribed for zoster or PHN previouslyc
Nonspecific neuropathic pain code (90–365 days post-zoster)
The primary analysis included patients with diagnosed, probable, and possible postherpetic
neuralgia. New prescriptions were defined as no previous prescriptions of the same
medication type 12 months to 2 weeks prior to zoster, to increase the likelihood of the
medication being prescribed for PHN (medications may have been prescribed for pain
management 2 weeks pre-zoster, if zoster initially presented without a rash).
a Read code for PHN in Clinical Practice Research Datalink or (for those with linked data) an
ICD-10 PHN code in the primary diagnosis field within any episode of linked Hospital
Episode Statistics.
b Prescriptions included anticonvulsants, tricyclic antidepressants, capsaicin cream, or
lidocaine patch.
cHere, previously is defined as a prescription 0–89 days following zoster. Medications
indicative of zoster were only considered in the 90- to 180-day period after zoster diag-
nosis (rather than 90–365 days) to reduce the chance of misclassifying other reasons for
medication use as PHN.
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different vaccination ages, e.g., #60 years in the United States17
and 70, 78, or 79 years18 in the United Kingdom).
General practice was included in all models as a random effect
to account for clustering, as data might be correlated within
practices.
Sensitivity analyses and bias assessments. We repeated the
main risk factor analysis (1) for PHN at 30 days following zoster;
(2) restricting PHN cases to diagnosed PHN only (see table 1 for
PHN definition); and (3) excluding possible misdiagnosed herpes
simplex patients (see appendix e-1 for definition of possible
herpes simplex patients). We tested for health care utilization bias
by assessing the association between PHN and hypothyroidism (a
chronic condition requiring high-level health care use,19 not
associated with PHN) and calculated mean yearly consultation
rate pre-zoster to confirm hypothyroidism patients had the same
opportunity for PHN diagnosis (i.e., via general practitioner [GP]
contact). We used multiple imputation by chained equations20 as
an alternative approach to account for missing data (9% of pa-
tients had missing data for BMI or smoking) (appendix e-III).
Bias may be introduced from excluding patients with ,365
days follow-up post-zoster if those included had a different asso-
ciation between our risk factors and PHN, compared to those
excluded. We repeated the main analysis, restricting our outcome
definition to PHN identified up to 120 and 180 days after zoster;
the follow-up requirements are less, thus any selection biases due
to excluding patients with insufficient follow-up is reduced.
Standard protocol approvals, registrations, and patient
consents. The study was approved by ISAC (application no.
11028) and the London School of Hygiene and Tropical Medi-
cine (application no. 5930).
RESULTS Of 144,959 patients with zoster, 119,413
were eligible for inclusion (figure e-1). Almost 60%
of the sample was female (table 2) and the median
age was 61 years (interquartile range 48–72, range
18–101). In total, 6,956 zoster patients (5.8%) devel-
oped PHN.
The risk of PHN rose with age (figure e-2) and the
association was nonlinear (p , 0.001, figure e-3). Pa-
tients 50–79 years had the steepest increased risk of PHN
(table 3); a 10-year increase in age within this age band
was associated with 70% increased risk of PHN (adjusted
OR [adjOR] 1.70, 99% confidence interval [CI] 1.63–
1.78), whereas the effect of a 10-year increase in age was
attenuated above age 80 years (adjOR 1.10, 99% CI
0.94–1.28). Women were more likely to develop PHN
than men, an association that remained after adjustment
(adjOR 1.19, 99% CI 1.10–1.27) (table 3).
Conditions and therapies causing severe immuno-
suppression were strong risk factors for PHN (tables 2
and 3). Patients with leukemia or lymphoma in the
previous 2 years, myeloma or other unspecified cel-
lular immune deficiencies ever, or recently taking
high-dose oral corticosteroids had over twice the risk
of developing PHN, compared to unaffected patients.
For HIV, the point estimate was also large; however,
only 6 of 99 HIV patients developed PHN, hence the
evidence for an association was weak (adjOR 2.17,
99% CI 0.64–7.37).
Table 2 Baseline characteristics of 119,413 eligible zoster cases and the
proportion developing postherpetic neuralgia (PHN)
Total cohort, n (%) No. (%) with PHN
Total 119,413 (100) 6,956 (5.8)
Demographic characteristics
Age, y
<50 33,010 (27.6) 588 (1.8)
50–79 72,744 (60.9) 4,623 (6.4)
‡80 13,659 (11.4) 1,745 (12.8)
Sex
Male 48,250 (40.4) 2,467 (5.1)
Female 71,163 (59.6) 4,489 (6.3)
Socioeconomic status (practice level)a
1 (least deprived) 24,058 (20.1) 1,282 (5.3)
2 23,653 (19.8) 1,288 (5.4)
3 24,568 (20.6) 1,443 (5.9)
4 24,994 (20.9) 1,557 (6.2)
5 (most deprived) 22,140 (18.5) 1,386 (6.3)
Severe immunosuppression
HIV 99 (0.1) 6 (6.1)
Leukemia 153 (0.1) 21 (13.7)
Lymphoma 314 (0.3) 40 (12.7)
Myeloma 312 (0.3) 53 (17.0)
Hematopoietic stem cell transplantation 17 (0.1) 5 (29.4)
Other unspecified cellular immune deficiencies 60 (0.1) 8 (13.3)
Oral corticosteroidsb 365 (0.3) 53 (14.5)
Other immunosuppressive therapyb 1,708 (1.4) 145 (8.5)
Autoimmune conditions
Rheumatoid arthritis 2,474 (2.1) 225 (9.1)
Systemic lupus erythematosus 307 (0.3) 29 (9.4)
Inflammatory bowel disease 1,469 (1.2) 110 (7.5)
Other comorbidities
COPD 5,060 (4.2) 669 (13.2)
Asthma 8,267 (6.9) 512 (6.2)
Chronic kidney disease 5,989 (5.0) 635 (10.6)
Depression 5,459 (4.6) 380 (7.0)
Personality disorder 774 (0.6) 53 (6.8)
Diabetes 8,492 (7.1) 789 (9.3)
Diabetes type
No diabetes 110,921 (92.9) 6,167 (5.6)
Type 1 282 (0.2) 10 (3.5)
Type 2 7,744 (6.5) 740 (9.6)
Type not specified 466 (0.4) 39 (8.4)
Recent cancer diagnosis 1,203 (1.0) 97 (8.1)
Health behaviors and characteristics
of zoster episode
Smokingc
Continued
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Of the autoimmune conditions, SLE was most
strongly associated with PHN (adjOR 1.76, 99%
CI 1.04–2.98) (tables 2 and 3). RA and IBD were
also associated with a higher PHN risk (9.1% and
7.5%, respectively), with some evidence they were
associated with between 10% and 20% increased risk
of PHN after adjustment for confounders; the effects
of these 2 conditions were less pronounced after ad-
justing for immunosuppressive drugs.
Of the other comorbidities assessed (tables 2 and
3), COPD was associated with a 53% increased risk
(PHN risk 13.2%; adjOR 1.53, 99% CI 1.35–1.72)
and recent depression a 40% increased risk (PHN risk
7.0%; adjOR 1.40, 99% CI 1.20–1.62). Asthma and
type 2 diabetes were associated with 20% increased
risk of PHN. After fully adjusting for confounders,
personality disorder, CKD, or recent cancer diagnosis
were not associated with PHN.
The overall risk of PHN among current smokers
was lower than the study sample overall (5.4% vs
5.8%); however, after adjusting for age, there was
around 30% increased risk of PHN in current smok-
ers (adjOR 1.27, 99% CI 1.15–1.39) (table 2). Being
underweight or obese was also associated with PHN.
PHN was more prevalent in patients with nontruncal
zoster (tables 2 and 3).
The effects of the risk factors on PHN were broadly
similar between those given and not given antivirals,
except for individuals with leukemia (p value for inter-
action 0.045), SLE (0.026), COPD (0.043), and
smoking (0.002); point estimates for their effect on
PHN appeared higher in those not given antivirals (fig-
ure 1). Post hoc analysis found no evidence that anti-
virals reduced the risk of PHN in patients with
immunosuppression (appendix e-V).
The effect of COPD (p value for interaction 0.006),
diabetes (0.004), currently smoking (0.006), or being
obese (0.037) were slightly stronger in patients ,70
years (table e-1); the effect of asthma (0.068), CKD
(0.018), diabetes (0.018), and being underweight or
obese were slightly stronger in patients ,60 years
(0.031) (table e-2). However, no clear patterns were
observed.
Sensitivity analyses.We reran the main analysis varying
the PHN definitions. Most CIs included the point esti-
mate from the main analysis (table e-3), except PHN at
30 days was associated with antiviral use (adjOR 1.12,
99% CI 1.06–1.18), yet less strongly associated with
ophthalmic zoster (adjOR 1.72, 99% CI 1.56–1.91);
restricting the outcome to diagnosed PHN only, the
effect of ophthalmic zoster (adjOR 2.67, 99% CI
2.24–3.19) and a 10-year increase in age between 50
and 79 years (adjOR 2.08, 99%CI 1.92–2.24) became
stronger and the effect of female sex disappeared
(adjOR 1.00, 99% CI 0.89–1.14) (table e-3).
We explored in post hoc analysis this loss of an
association with female sex (using the primary PHN
definition) (tables e-4 and e-5). The effect of female
sex on PHN was driven by cases of PHN defined
using tricyclic antidepressant use, yet we found evi-
dence suggesting prescribing practices for PHN differ
by sex (appendix e-IV).
Of 7,416 patients with hypothyroidism, 599 (8.1%)
developed PHN. The fully adjusted OR between hypo-
thyroidism and PHN indicated no association (adjOR
1.01, 99% CI 0.90–1.14, adjusted for variables in table
3, model 2); furthermore, mean yearly consultation rates
among patients with our risk factors of interest were
variable (table e-6), showing no consistent pattern with
PHN risk.
Accounting for missing BMI and smoking data
using multiple imputation made no difference in
the results (table e-7). Restricting to shorter follow-
up periods (specifically 120 and 180 days) also had
no major effect on the results (figure e-4).
DISCUSSION This study shows that older age and
severe immunosuppression, such as recently having
lymphoma or leukemia, are the strongest risk factors
for PHN among zoster patients. Although immuno-
suppressed patients are not currently eligible for vac-
cination, promising research on a new subunit zoster
vaccine (HZ/su) may enable vaccination within this
group.21 Other risk factors included autoimmune con-
ditions (RA, SLE, and IBD), COPD, depression,
Table 2 Continued
Total cohort, n (%) No. (%) with PHN
Nonsmoker 45,775 (38.3) 2,326 (5.1)
Current smoker 30,756 (25.8) 1,646 (5.4)
Ex-smoker 41,731 (34.9) 2,946 (7.1)
BMI categoryc
Underweight (BMI <18.5) 2,150 (1.8) 188 (8.7)
Normal weight (BMI 18.5–24.9) 42,051 (35.2) 2,398 (5.7)
Overweight (BMI 25–30) 39,934 (33.4) 2,395 (6.0)
Obese (BMI ‡30) 24,249 (20.3) 1,560 (6.4)
Antiviral record within 7 days of zoster 68,882 (57.7) 4,248 (6.2)
Anatomical site of zoster
Site unspecified 113,000 (94.6) 6,214 (5.5)
Nontruncal (excluding ophthalmic zoster) 736 (0.6) 74 (10.1)
Ophthalmic zoster 5,677 (4.8) 668 (11.8)
Abbreviations: BMI 5 body mass index; COPD 5 chronic obstructive pulmonary disease.
aMeasured by index of multiple deprivation score.
b Includes patients prescribed a 14-day (or longer) course of high dose (at least 20 mg per
day) oral corticosteroids medications in the month before zoster diagnosis, or patients
taking other immunosuppressive medications less than 1 month prior to zoster diagnosis.
cMissing data: complete for all variables, except smoking (n 5 1,151 [1.0%] missing) and
BMI category (n 5 11,029 [9.3%] missing).
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Table 3 Unadjusted and adjusted associations between postherpetic neuralgia and demographic risk factors, comorbidities, and health
behaviors
Unadjusted
OR (99% CI)
Age-adjusted
OR (99% CI)
Model 1: Adjusted
ORa (99% CI)
Model 2: Model 1
additionally adjusted for
immunosuppressive
therapies, OR (99% CI)
Demographic characteristics
Age, y (estimated ORs for 10-year increase in
age within the specified age band)b
Among those aged <50 y 1.48 (1.35–1.63) — 1.42 (1.28–1.58) 1.42 (1.28–1.57)
Among those aged 50–79 y 1.74 (1.68–1.81) — 1.70 (1.63–1.78) 1.70 (1.63–1.78)
Among those aged ‡80 y 0.99 (0.87–1.14) — 1.09 (0.94–1.27) 1.10 (0.94–1.28)
Female 1.25 (1.17–1.34) 1.17 (1.09–1.25) 1.19 (1.10–1.28) 1.19 (1.10–1.27)
Socioeconomic status (practice level)c
1 (least deprived) 1.00 1.00 1.00 1.00
2 1.01 (0.89–1.15) 1.05 (0.92–1.19) 1.04 (0.91–1.18) 1.04 (0.91–1.18)
3 1.09 (0.96–1.24) 1.09 (0.96–1.24) 1.09 (0.96–1.24) 1.09 (0.96–1.24)
4 1.17 (1.03–1.33) 1.19 (1.05–1.35) 1.17 (1.03–1.32) 1.17 (1.03–1.32)
5 (most deprived) 1.19 (1.04–1.35) 1.26 (1.11–1.44) 1.20 (1.06–1.37) 1.20 (1.06–1.37)
Severe immunosuppression
HIV 1.04 (0.35–3.08) 2.40 (0.80–7.27) 2.23 (0.66–7.53) 2.17 (0.64–7.37)
Leukemia 2.65 (1.44–4.87) 2.32 (1.25–4.33) 2.06 (1.08–3.95) 2.07 (1.08–3.96)
Lymphoma 2.38 (1.54–3.70) 2.39 (1.53–3.75) 2.44 (1.52–3.90) 2.45 (1.53–3.92)
Myeloma 3.33 (2.25–4.93) 2.36 (1.58–3.51) 2.18 (1.44–3.31) 2.17 (1.43–3.29)
Hematopoietic stem cell transplantation 6.89 (1.73–27.52) 11.25 (2.73–46.44) 5.85 (1.30–26.29) 5.91 (1.32–26.59)
Other unspecified cellular immune deficiencies 2.43 (0.91–6.52) 2.19 (0.80–6.02) 2.15 (0.78–5.97) 2.12 (0.77–5.89)
Oral corticosteroidsd 2.76 (1.88–4.07) 2.55 (1.71–3.78) — 2.26 (1.51–3.40)
Other immunosuppressive therapyd 1.52 (1.21–1.91) 1.46 (1.16–1.84) — 1.21 (0.92–1.58)
Autoimmune conditions
Rheumatoid arthritis 1.64 (1.36–1.97) 1.27 (1.06–1.54) 1.20 (0.99–1.46) 1.13 (0.91–1.39)
Systemic lupus erythematosus 1.70 (1.03–2.82) 1.95 (1.16–3.27) 1.82 (1.08–3.08) 1.76 (1.04–2.98)
Inflammatory bowel disease 1.31 (1.01–1.70) 1.33 (1.03–1.74) 1.27 (0.97–1.67) 1.22 (0.93–1.60)
Other comorbidities
COPD 2.60 (2.32–2.91) 1.66 (1.48–1.86) 1.54 (1.36–1.74) 1.53 (1.35–1.72)
Asthma 1.07 (0.95–1.21) 1.22 (1.08–1.39) 1.21 (1.07–1.38) 1.21 (1.06–1.37)
Chronic kidney disease 2.01 (1.79–2.25) 1.17 (1.04–1.32) 1.09 (0.96–1.23) 1.08 (0.96–1.22)
Depression 1.21 (1.05–1.40) 1.53 (1.32–1.77) 1.39 (1.20–1.62) 1.40 (1.20–1.62)
Personality disorder 1.18 (0.81–1.70) 1.37 (0.94–1.99) 1.25 (0.85–1.84) 1.25 (0.85–1.85)
Diabetes 1.74 (1.57–1.93) 1.26 (1.13–1.40) 1.19 (1.07–1.33) 1.19 (1.07–1.33)
Diabetes type
No diabetes 1.00 1.00 1.00 1.00
Type 1 0.62 (0.27–1.44) 1.45 (0.62–3.36) 1.53 (0.66–3.55) 1.51 (0.65–3.51)
Type 2 1.79 (1.61–1.99) 1.24 (1.12–1.38) 1.17 (1.05–1.31) 1.17 (1.05–1.31)
Type not specified 1.55 (1.00–2.39) 1.62 (1.04–2.52) 1.54 (0.99–2.41) 1.54 (0.98–2.40)
Recent cancer diagnosis 1.42 (1.08–1.88) 1.05 (0.79–1.38) 1.06 (0.79–1.41) 1.06 (0.79–1.41)
Health behaviors and characteristics of
zoster episode
Smoking
Nonsmoker 1.00 1.00 1.00 1.00
Continued
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diabetes, asthma, lower socioeconomic status, smoking,
being underweight or overweight, and nontruncal zoster.
Antivirals given at zoster were not associated with PHN
risk overall, but there was some weak evidence that their
use mitigated the increased risks associated with leuke-
mia, SLE, COPD, and smoking.
This study addresses an absence in the literature of
well-powered studies assessing PHN risk factors.10,11
The study benefits from being the largest study address-
ing this question; being population-based; using a dataset
broadly representative of the United Kingdom13; tightly
accounting for confounding by age; and using a more
precise definition of PHN than earlier studies using
routinely collected data.
Despite its strengths, this study has some limita-
tions. Although we attempted to reduce misclassifica-
tion of PHN by basing our definition on a validated
method for administrative data,15 PHN incidence is
lower than in previous studies (5.8% vs 7.2% in an
Icelandic study with active follow-up of similar aged
zoster cases22). The reported prevalence of PHN varies
hugely across studies. We used a 90-day (rather than
30-day) definition and included patients ,50 years
old, which may explain the relatively low PHN prev-
alence. However, some PHN diagnoses could have
been missed. Unidentified cases are likely those
patients with mild pain, who used over-the-counter
medications for initial pain relief or (if GP-prescribed
treatments were ineffective) for follow-on pain relief.
These findings are therefore likely to be generalizable to
patients with severe PHN. Another explanation for the
low prevalence may be that some immunocompro-
mised patients are treated exclusively in secondary care;
however, this is likely to be a few cases only, because
PHN is largely treated in primary care.
Certain clinical features of acute zoster are
accepted PHN risk factors, including prodromal pain
and increased rash severity.10,11 In CPRD, these data
are unavailable. These features may lie on the causal
pathway or be mediators between our exposures and
PHN. For example, patients with leukemia may expe-
rience greater viral load, which manifests as a severe
rash and increase PHN risk. It would be inappropriate
to control for rash severity, as we want the total effect of
leukemia on PHN; lacking data on these clinical fea-
tures is therefore unlikely to limit our findings.
In numerous studies, increasing age is associated
with a sharp increase in PHN risk.3,23 Our study iden-
tified a nonlinear age effect; PHN risk increased steeply
between 50 and 79 years and attenuated after age 80.
A Dutch cohort study among 837 zoster patients24 sug-
gested PHN incidence continues to increase in individ-
uals.80 years; however, PHN was defined as analgesic
prescription 3 months post-zoster, potentially causing
Table 3 Continued
Unadjusted
OR (99% CI)
Age-adjusted
OR (99% CI)
Model 1: Adjusted
ORa (99% CI)
Model 2: Model 1
additionally adjusted for
immunosuppressive
therapies, OR (99% CI)
Current smoker 1.06 (0.97–1.15) 1.32 (1.21–1.45) 1.26 (1.15–1.39) 1.27 (1.15–1.39)
Ex-smoker 1.42 (1.32–1.54) 1.21 (1.12–1.30) 1.14 (1.05–1.24) 1.14 (1.05–1.24)
BMI category
Underweight (BMI <18.5) 1.58 (1.29–1.94) 1.38 (1.12–1.70) 1.25 (1.01–1.54) 1.25 (1.01–1.54)
Normal weight (BMI 18.5–24.9) 1.00 1.00 1.00 1.00
Overweight (BMI 5–30) 1.05 (0.98–1.14) 0.99 (0.92–1.07) 1.01 (0.93–1.09) 1.01 (0.93–1.09)
Obese (BMI ‡30) 1.13 (1.04–1.24) 1.18 (1.08–1.29) 1.13 (1.03–1.24) 1.13 (1.03–1.24)
Antiviral record within 7 days of zoster 1.16 (1.09–1.24) 1.05 (0.98–1.12) 1.04 (0.97–1.12) 1.04 (0.97–1.11)
Anatomical site of zoster
Site unspecified 1.00 1.00 1.00 1.00
Nontruncal (excluding ophthalmic zoster) 1.94 (1.41–2.67) 2.34 (1.68–3.25) 2.20 (1.54–3.12) 2.19 (1.54–3.11)
Ophthalmic zoster 2.29 (2.05–2.56) 1.93 (1.72–2.16) 1.94 (1.73–2.19) 1.95 (1.73–2.19)
Abbreviations: BMI 5 body mass index; CI 5 confidence interval; COPD 5 chronic obstructive pulmonary disease; OR 5 odds ratio.
a Adjusted for age, sex, socioeconomic status, HIV, leukemia, lymphoma, myeloma, hematopoietic stem cell transplantation, other unspecified cellular
immune deficiencies, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, COPD, asthma, chronic kidney disease, depression,
personality disorder, diabetes, recent cancer diagnosis, smoking, BMI category, site of zoster, and antivirals.
bORs estimate the effect of a 10-year increase in age on postherpetic neuralgia derived, in age groups ,50, 50–79, and $80 years, from piecewise linear
splines.
cMeasured by index of multiple deprivation score.
d Includes patients prescribed a 14-day (or longer) course of high dose (at least 20 mg per day) oral corticosteroids medications in the month before zoster
diagnosis, or patients taking other immunosuppressive medications less than 1 month prior to zoster diagnosis. There was no evidence of collinearity
between variables (indicated by a 20% increase in standard errors in the fully, vs age-adjusted, model for each risk factor).
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Figure 1 Adjusted associations between postherpetic neuralgia and demographic risk factors and health
behaviors and comorbidities, stratified by whether a patient received antivirals during acute zoster
Adjusted associations between postherpetic neuralgia and (A) demographic risk factors and health behaviors and (B) comor-
bidities, stratified by whether a patient received antivirals during acute zoster. Analyses are restricted to 69,661 patients
for whom antiviral status was most likely to be available. Full results can be found in table e-8. Adjusted for age, sex, socio-
economic status (SES), HIV, leukemia, lymphoma, myeloma, immunosuppressive therapies, rheumatoid arthritis, systemic
lupus erythematosus (SLE), inflammatory bowel disease, chronic obstructive pulmonary disease (COPD), asthma, chronic
kidney disease, depression, personality disorder, diabetes, recent cancer diagnosis, smoking, and body mass index (BMI)
category. Hematopoietic stem cell transplantation and other unspecified cellular immune deficiencies were excluded due
Continued
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misclassification, particularly among older individuals.
Other studies report PHN risk lessening around 80
years.25–27 Our observed effect may arise from underas-
certainment of PHN in patients.80 years due to frailty
preventing GP attendance or PHN-associated pain being
superseded by other comorbidities.
Previous studies have not identified depression as
a risk factor for PHN,28–31 unlike our study. We
acknowledge that our result may be driven by patients
requiring tricyclic antidepressants for depression, and
being misclassified as PHN cases; when restricting
PHN cases to diagnosed PHN only, the association
with depression disappeared (adjOR 1.12, 99% CI
0.84–1.49). However, the wide CIs suggest there may
have been insufficient power to detect an effect.
The study found no evidence that antivirals pro-
tected against PHN. This is unlikely to be attributed
to inadequate dosing, as 93% of treated patients
received at least the recommended minimum antiviral
dose. However, other limitations could explain this
null finding. In primary care, patients with severe zos-
ter are recommended to receive antivirals, yet are also
more likely to develop PHN. This may introduce
confounding by indication and mask a protective
effect. Also, trial data has assessed the efficacy of anti-
virals administered within 72 hours of rash onset.8
Although 97.5% of patients were prescribed antivirals
on the day of zoster diagnosis, zoster treatment initi-
ation may occur.72 hours after rash onset, when the
effect of antivirals is unproven. Although data on time
from actual rash onset to presentation at general prac-
titioners are not available in this dataset, 2 previous
UK studies suggest 50%–65% of patients present
within 72 hours,32,33 leaving a number of patients
treated after 72 hours from rash onset.
Our recent systematic review of PHN risk factors
concluded there was no consensus regarding immu-
nosuppression as a risk factor for PHN.10 The present
study demonstrates that immunosuppression is asso-
ciated with greater PHN risk and the study had suf-
ficient power to assess the effect of specific
immunosuppressive conditions and therapies on
PHN risk. Our study is also novel in identifying
autoimmune conditions as PHN risk factors; autoim-
mune conditions had scarcely been assessed previ-
ously, though SLE was associated with over 2-fold
increased risk of PHN in a large Taiwanese cohort
study.34
Disentangling the role of diseases and their drug
treatments on the PHN risk is challenging. There was
little evidence that the increased risks associated with
severely immunosuppressive conditions were mediated
by immunosuppressive drugs. However, treatment such
as chemotherapy, given in secondary care, is not cap-
tured in CPRD and probably explains at least part of
the increased risk. The effects of IBD and RA on
PHNwere less pronounced after adjusting for immuno-
suppressive treatments, suggesting that the association is
driven predominantly by exposure to these drugs. By
contrast, the effect of SLE did not appear to be mediated
by immunosuppressive therapies, although CRPD lacks
reliable data on newer biological therapies.
Establishing the role of severe immunosuppression
and autoimmune conditions on PHN risk may help
shed light on the underlying pathophysiologic mecha-
nisms that lead to PHN, which are poorly understood.
Two key etiologic hypotheses are that PHN is caused
by a persistence of varicella-zoster virus following zoster
or by increased neuronal excitability and alteration of
pain perception.6,35 Our finding of a strong association
between immunosuppression and PHN risk seems to
support the former hypothesis; lower cell-mediated
immunity may lead to higher levels of virus during
acute infection and thus an increased risk of PHN.
Cost-effectiveness studies are needed to determine
the value in vaccinating patients with identified risk fac-
tors for PHN against zoster. Those of older age and with
severe immunosuppression were at the highest risk of
PHN. Strategies to prevent zoster in patients with severe
immunosuppression are an increasing priority as these
patients are not currently eligible for zoster vaccination,
although the new development of a subunit vaccine pro-
vides a promising alternative.21
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Figure 1 legend, continued:
to too few numbers. Patients excluded were those with zoster diagnosed in Hospital Episode Statistics (HES) or having
a HES visit for zoster 7 days after diagnosis (n 5 494), patients who were not HES-linked (n 5 45,418), and patients with
nontruncal zoster (n5 3,840), as their antiviral use may not be recorded in Clinical Practice Research Datalink. 1Odds ratios
estimate the effect of a 10-year increase in age on postherpetic neuralgia derived, in age groups ,50, 50–79, and $80
years, from piecewise linear splines. 2Measured by index of multiple deprivation score (IMD15 least deprived, IMD55most
deprived). 3Includes patients prescribed a 14-day (or longer) course of high dose (at least 20mg per day) oral corticosteroids
medications in the month before zoster diagnosis, or patients taking other immunosuppressive medications less than 1
month prior to zoster diagnosis. Interaction terms between antiviral use and other risk factors were added to the model one
at a time. CI 5 confidence interval.
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